Anti-rheumatic drug iguratimod (T-614) alleviates cancer-induced bone destruction via down-regulating interleukin-6 production in a nuclear factor-κB-dependent manner

Abstract

Cytokines are believed to be involved in a “vicious circle” of progressive interactions in bone metastasis. Iguratimod is a novel anti-rheumatic drug which is reported to have the capability of anti-cytokines. In this study, a rat model was constructed to investigate the effect of iguratimod on bone metastasis and it was found that iguratimod alleviated cancer-induced bone destruction. To further explore whether an anti-tumor activity of iguratimod contributes to the effect of bone resorption suppression, two human breast cancer cell lines MDA-MB-231 and MCF-7 were studied. The effect of iguratimod on tumor proliferation was detected by CCK-8 assay and flow cytometry. The effects of iguratimod on migration and invasion of cancer cells were determined by wound-healing and Transwell assays. Results showed that high dose (30 μg/mL) iguratimod slightly suppressed the proliferation of cancer cells but failed to inhibit their migration and invasion capacity. Interestingly, iguratimod decreased the transcription level of IL-6 in MDA-MB-231 cells in a concentration-dependent manner. Moreover, iguratimod partially impaired NF-κB signaling by suppressing the phosphorylation of NF-κB p65 subunit. Our findings indicated that iguratimod may alleviate bone destruction by partially decreasing the expression of IL-6 in an NF-κB-dependent manner, while it has little effect on the tumor proliferation and invasion.

Keywords

iguratimod / bone metastasis / bone destruction / cytokines / nuclear factor-κB

References

[1] WeiY, SunX, HuaM, et al. . Inhibitory effect of a novel antirheumatic drug T-614 on the IL-6-induced RANKL/ OPG, IL-17, and MMP-3 expression in synovial fibroblasts from rheumatoid arthritis atients. Biomed Res Int, 2015, 2015: 21468

[2] AikawaY, YamamotoM, YamamotoT, et al. . An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS-and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res, 2002, 51(4): 188-194 PMID: 12058956

[3] KohnoM, AikawaY, TsubouchiY, et al. . Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol, 2001, 28(12): 2591-2596 PMID: 11764202

[4] KawakamiA, TsuboiM, UrayamaS, et al. . Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med, 1999, 133(6): 566-574 PMID: 10360631

[5] DuF, LuLJ, FuQ, et al. . T-614, a novel immuneomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis Res Ther, 2008, 10(6): R136 PMID: 19019215 PMCID: 2656239

[6] RoodmanGD. Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev, 2012, 31(3-4): 569-578 PMID: 22706844

[7] SosnoskiDM, KrishnanV, KraemerWJ, et al. . Changes in cytokines of the bone microenvironment during breast cancer metastasis. Int J Breast Cancer, 2012, 2012: 160265 PMID: 22315691 PMCID: 3270522

[8] FiliS, KaralakiM, SchallerB. Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors. Cancer Lett, 2009, 283(1): 10-19 PMID: 19201081

[9] GrossmannM, NakamuraY, GrumontR, et al. . New insights into the roles of ReL/NF-kappa B transcription factors in immune function, hemopoiesis and human disease. Int J Biochem Cell Biol, 1999, 31(10): 1209-1219 PMID: 10582348

[10] Di DonatoJA, MercurioF, KarinM. NF-kappaB and the link between inflammation and cancer. Immunol Rev, 2012, 246(1): 379-400

[11] GuanXH, FuQC, ShiD, et al. . Activation of spinal chemokine receptor CXCR3 mediates bone cancer pain through an Akt-ERK crosstalk pathway in rats. Exp Neurol, 2015, 263: 39-49 PMID: 25281485

[12] CaoF, GaoF, XuAJ, et al. . Regulation of spinal neuroimmune responses by prolonged morphine treatment in a rat model of cancer induced bone pain. Brain Res, 2010, 1326: 162-173 PMID: 20176002

[13] LiuX, BuH, LiuC, et al. . Inhibition of glial activation in rostral ventromedial medulla attenuates mechanical allodynia in a rat model of cancer-induced bone pain. J Huazhong Univ Sci Technolog Med Sci, 2012, 32(2): 291-298 PMID: 22528236

[14] BuH, ShuB, GaoF, et al. . Spinal IFN-gamma-induced protein-10 (CXCL10) mediates metastatic breast cancer-induced bone pain by activation of microglia in rat models. Breast Cancer Res Treat, 2014, 143(2): 255-263 PMID: 24337539

[15] OkamuraK, YonemotoY, OkuraC, et al. . Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis. Mod Rheumatol, 2015, 25(2): 235-240 PMID: 25065917

[16] HaraM, AbeT, SugawaraS, et al. . Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol, 2007, 17(1): 1-9 PMID: 17278015

[17] HaraM, AbeT, SugawaraS, et al. . Long-term safety study of iguratimod in patients with rheumatoid arthritis. Mod Rheumato, 2007, 17(1): 10-16

[18] TanakaK, YamamotoT, AikawaY, et al. . Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology, 2003, 42(11): 1365-1371 PMID: 12810927

[19] GuanX, FuQ, XiongB, et al. . Activation of PI3Kgamma/Akt pathway mediates bone cancer pain in rats. J Neurochem, 2015, 134(3): 590-600 PMID: 25919859

[20] ZhouYQ, GaoHY, GuanXH, et al. . Chemokines and their receptors: Potential therapeutic targets for bone cancer pain. Curr Pharm Des, 2015, 21(34): 5029-5033 PMID: 26320755

[21] KeC, GaoF, TianX, et al. . Slit2/Robo1 mediation of synaptic plasticity contributes to bone cancer pain. Mol Neurobiol, 2016

[22] ZhouYQ, LiuZ, LiuHQ, et al. . Targeting glia for bone cancer pain. Expert Opin Ther Targets., 2016

[23] KinderM, ChislockE, BussardKM, et al. . Metastatic breast cancer induces an osteoblast inflammatory response. Exp Cell Res, 2008, 314(1): 173-183 PMID: 17976581

[24] RoodmanGD. Mechanisms of bone metastasis. N Engl J Med, 2004, 350(16): 1655-1664 PMID: 15084698

[25] AraT, DeclerckYA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer, 2010, 46(7): 1223-1231 PMID: 20335016 PMCID: 2917917

[26] SteeveKT, MarcP, SandrineT, et al. . IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev, 2004, 15(1): 49-60

[27] NieB, ZhouSQ, FangX, et al. . The function and meaning of receptor activator of NF-kappaB ligand in arterial calcification. J Huazhong Univ Sci Technolog Med Sci, 2015, 35(5): 666-671 PMID: 26489619

[28] DuF, LuLJ, TengJL, et al. . T-614 alters the production of matrix metalloproteinases (MMP-1 and MMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro. Int Immunopharmacol, 2012, 13(1): 54-60 PMID: 22446297

[29] LuoQ, SunY, LiuW, et al. . A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol, 2013, 191(10): 4969-4978 PMID: 24123677

[30] XuY, ZhuQ, SongJ, et al. . Regulatory effect of iguratimod on the balance of Th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis. Mediators Inflamm, 2015, 2015: 356040 PMID: 26713003 PMCID: 4680115

[31] BaeuerlePA, HenkelT. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol, 1994, 12: 141-179 PMID: 8011280

[32] AkiraS, KishimotoT. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev, 1992, 127: 25-50 PMID: 1380488

[33] LibermannTA, BaltimoreD. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol, 1990, 10(5): 2327-2334 PMID: 2183031 PMCID: 360580

[34] ZhouYQ, LiuZ, LiuZH, et al. . Interleukin-6: an emerging regulator of pathological pain. J Neuroinflammation, 2016, 13(1): 141 PMID: 27267059 PMCID: 4897919

[35] KarinM, GretenFR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol, 2005, 5(10): 749-759 PMID: 16175180

[36] KongFC, ZhangJQ, ZengC, et al. . Inhibitory effects of parthenolide on the activity of NF-kappaB in multiple myeloma via targeting TRAF6. J Huazhong Univ Sci Technolog Med Sci, 2015, 35(3): 343-349 PMID: 26072071

[37] JiGQ, ChenRQ, WangL. Anti-inflammatory activity of atractylenolide III through inhibition of nuclear factor-kappaB and mitogen-activated protein kinase pathways in mouse macrophages. Immunopharmacol Immunotoxicol, 2016, 38(2): 98-102 PMID: 26667579

[38] TsubakiM, TakedaT, KinoT, et al. . Mangiferin suppresses CIA by suppressing the expression of TNF-alpha, IL-6, IL-1beta, and RANKL through inhibiting the activation of NF-kappaB and ERK1/2. Am J Transl Res, 2015, 7(8): 1371-1381 PMID: 26396668 PMCID: 4568793

[39] PacificoF, LeonardiA. NF-kappaB in solid tumors. Biochem Pharmacol, 2006, 72(9): 1142-1152 PMID: 16956585

[40] Van WaesC. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res, 2007, 13(4): 1076-1082 PMID: 17317814

[41] TanakaK, UrataN, MikamiM, et al. . Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice. Inflamm Res, 2007, 56(1): 17-23 PMID: 17334666

[42] BussardKM, VenzonDJ, MastroAM. Osteoblasts are a major source of inflammatory cytokines in the tumor microenvironment of bone metastatic breast cancer. J Cell Biochem, 2010, 111(5): 1138-1148 PMID: 20683902 PMCID: 3654838